Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Piflufolastat F18 - Curium Pharma/Progenics Pharmaceuticals

Drug Profile

Piflufolastat F18 - Curium Pharma/Progenics Pharmaceuticals

Alternative Names: 18FDCFPyL (PyL-PSMA) PET/CT; [18F]-DCFPyL; DCFPyL-18F; Fluorine-18 DCFPyL; Fluorine-18 piflufolastat; Piflufolastat F 18 injection; PyL; PYLARIFY; PYLCLARI

Latest Information Update: 19 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Curium Pharma; Progenics Pharmaceuticals
  • Class Amides; Carboxylic acids; Fluorinated hydrocarbons; Imaging agents; Pyridines; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules; Urea compounds
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 17 Jun 2024 Launched for Prostate cancer (Diagnosis) in Austria (IV)
  • 09 May 2024 Launched for Prostate cancer (Diagnosis) in Germany (IV)
  • 09 Apr 2024 Launched for Prostate cancer (Diagnosis) in Netherlands (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top